Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Clinical issues in use of atypical antipsychotics for depressed patients.

Pae CU, Patkar AA.

CNS Drugs. 2013 May;27 Suppl 1:S39-45. doi: 10.1007/s40263-012-0032-z. Review.

PMID:
23709360
2.

Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.

Kato M, Chang CM.

CNS Drugs. 2013 May;27 Suppl 1:S11-9. doi: 10.1007/s40263-012-0029-7. Review.

PMID:
23709358
3.

A systematic review of augmentation strategies for patients with major depressive disorder.

Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME.

Psychopharmacol Bull. 2009;42(3):57-90. Review.

PMID:
19752841
4.

Therapeutic potential of new second generation antipsychotics for major depressive disorder.

McElroy SL, Guerdjikova A, Mori N, Keck PE Jr.

Expert Opin Investig Drugs. 2010 Dec;19(12):1527-44. doi: 10.1517/13543784.2010.538048. Review.

PMID:
21105856
5.

Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder.

Patkar AA, Pae CU.

CNS Drugs. 2013 May;27 Suppl 1:S29-37. doi: 10.1007/s40263-012-0031-0. Review.

PMID:
23709359
6.

Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.

Wright BM, Eiland EH 3rd, Lorenz R.

Pharmacotherapy. 2013 Mar;33(3):344-59. doi: 10.1002/phar.1204. Review.

PMID:
23456734
7.

Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.

Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU.

Expert Rev Neurother. 2013 Jul;13(7):851-70. doi: 10.1586/14737175.2013.811901. Review.

PMID:
23898855
8.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
9.

Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.

Maher AR, Theodore G.

J Manag Care Pharm. 2012 Jun;18(5 Suppl B):S1-20. Review.

PMID:
22784311
10.

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, Falkai P, Kapur S, Leucht S, Licht R, Naber D, O'Keane V, Papakostas G, Vieta E, Zohar J.

Eur Neuropsychopharmacol. 2009 Jul;19(7):520-32. doi: 10.1016/j.euroneuro.2009.04.003. Epub 2009 May 2.

PMID:
19411165
11.

The efficacy and tolerability of bupropion in the treatment of major depressive disorder.

Moreira R.

Clin Drug Investig. 2011 Oct 19;31 Suppl 1:5-17. doi: 10.2165/1159616-S0-000000000-00000. Review.

PMID:
22015858
12.

Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.

Lin CY, Tsai GE, Wang HS, Wu YH, Chiou CC, Wu VY, Lane HY.

J Clin Psychiatry. 2014 Sep;75(9):e924-31. doi: 10.4088/JCP.13m08843.

PMID:
25295435
13.

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials.

Nelson JC, Papakostas GI.

Am J Psychiatry. 2009 Sep;166(9):980-91. doi: 10.1176/appi.ajp.2009.09030312. Epub 2009 Aug 17.

PMID:
19687129
14.

Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians.

Gartlehner G, Gaynes BN, Amick HR, Asher GN, Morgan LC, Coker-Schwimmer E, Forneris C, Boland E, Lux LJ, Gaylord S, Bann C, Pierl CB, Lohr KN.

Ann Intern Med. 2016 Mar 1;164(5):331-41. doi: 10.7326/M15-1813. Epub 2015 Dec 8. Review.

PMID:
26857743
15.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
16.

Are atypical antipsychotic drugs also atypical antidepressants?

Parker G, Malhi G.

Aust N Z J Psychiatry. 2001 Oct;35(5):631-8. Review.

PMID:
11551279
17.

[Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].

Favré P.

Encephale. 2012 Feb;38(1):86-96. doi: 10.1016/j.encep.2011.11.003. Epub 2011 Dec 10. Review. French.

PMID:
22381728
18.

An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder.

Leuchter AF, Lesser IM, Trivedi MH, Rush AJ, Morris DW, Warden D, Fava M, Wisniewski SR, Luther JF, Perales M, Gaynes BN, Stewart JW.

J Psychiatr Pract. 2008 Sep;14(5):271-80. doi: 10.1097/01.pra.0000336754.19566.65.

19.

Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.

Gao K, Kemp DE, Fein E, Wang Z, Fang Y, Ganocy SJ, Calabrese JR.

J Clin Psychiatry. 2011 Aug;72(8):1063-71. doi: 10.4088/JCP.09r05535gre. Epub 2010 Oct 19.

20.

Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.

Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S; and the VAST-D Investigators, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB 3rd, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT.

JAMA. 2017 Jul 11;318(2):132-145. doi: 10.1001/jama.2017.8036.

PMID:
28697253

Supplemental Content

Support Center